Related by context. All words. (Click for frequent words.) 68 Amigal 67 obatoclax 67 INCB# [002] 67 PXD# 67 axitinib 66 elotuzumab 66 PRT# 65 tamibarotene 65 AQ4N 65 forodesine 65 ganetespib 65 JAK inhibitor 65 phase IIb clinical 64 Zerenex 64 MEK inhibitors 64 TELCYTA 64 MBP# [001] 64 TOCOSOL Paclitaxel 64 ponatinib 64 pralatrexate 64 IMA# 64 #D#C# 64 valopicitabine 64 Amrubicin 64 alvespimycin 64 daclizumab 64 HGS# 63 AP# [003] 63 amrubicin 63 AVEO 63 carfilzomib 63 tanespimycin 63 Phenoptin 63 EOquin 63 Proxinium TM 63 Phase IIb trials 63 Archexin 63 Allovectin 7 ® 63 Azedra 63 Asentar 63 Alzhemed TM 63 Phase 2b trial 63 Allovectin 7 R 63 vandetanib 63 satraplatin 63 perifosine 63 Allovectin 7 63 XL# [003] 63 MOZOBIL 63 MGCD# [001] 63 ruxolitinib 63 HuMax CD4 63 IRX 2 63 Insegia 63 INT# [002] 63 MEK inhibitor RDEA# 62 HGS ETR1 62 OMAPRO 62 PREOS 62 DAVANAT 62 dirucotide 62 Phase III trials 62 pradefovir 62 Tamibarotene 62 HuLuc# 62 phase IIa clinical 62 vosaroxin 62 personalized immunotherapy 62 bardoxolone 62 otelixizumab 62 OncoVEX GM CSF 62 ularitide 62 ProSavin 62 MyVax R 62 eniluracil 62 FOLOTYN 62 atacicept 62 oral ridaforolimus 62 teriflunomide 62 elesclomol 62 Sym# 62 Icatibant 62 PEG SN# 62 Traficet EN 62 Phase 1b trial 61 Azedra TM 61 HspE7 61 Phase 2b study 61 HuMax CD# 61 nimotuzumab 61 drug ISA# 61 pomalidomide 61 Neo Urinary Conduit 61 evaluating tivozanib 61 mapatumumab 61 HuMax EGFr 61 PEG Interferon lambda 61 XmAb# 61 TORISEL 61 voreloxin 61 Surfaxin LS 61 fidaxomicin 61 registrational 61 AEG# 61 Phase Ib 61 blinatumomab 61 phase IIb 61 relapsed multiple myeloma 61 OvaRex ® MAb 61 metaglidasen 61 HQK 61 ocrelizumab 61 refractory multiple myeloma 61 CTAP# Capsules 61 HRPC 61 docetaxel Taxotere R 61 Bezielle 61 registrational trial 61 talactoferrin 61 HGS ETR2 61 oral prodrug 61 confirmatory Phase III 61 PF # [001] 61 Xanafide 61 trabectedin 61 sapacitabine 61 Stedivaze 61 ZK EPO 61 DXL# 61 TRO# 61 Phase 1b 61 AVN# [001] 61 Phase 2a trial 61 Annamycin 61 teduglutide 61 ASONEP 61 lomitapide 61 Panzem R NCD 61 oral deforolimus 61 triple VEGF receptor 61 ALN VSP 61 PANVAC VF 61 betrixaban 61 SNT MC# 61 pertuzumab 61 CoFactor 61 Solazed TM 61 DB# [003] 60 sorafenib 60 Factor VIIa 60 BiTE antibody 60 GATTEX 60 erlotinib Tarceva ® 60 dacetuzumab 60 ENMD # 60 luliconazole 60 CYT# 60 ulimorelin 60 docetaxel Taxotere ® 60 orBec R 60 Phase III clinical 60 anticancer agent 60 TG# [003] 60 favorable tolerability 60 FOLFOX6 chemotherapy regimen 60 picoplatin 60 Phase IIb clinical 60 Phase III clinical trials 60 PS# [001] 60 XL# XL# XL# XL# 60 RG# [001] 60 CEQ# 60 clofarabine 60 INCB# [001] 60 Aurora kinase inhibitor 60 GALNS 60 OvaRex R 60 apremilast 60 LEP ETU 60 GED aPC 60 CCX# 60 Plicera 60 tesetaxel 60 TELINTRA 60 SCH # 60 CR# vcMMAE 60 regorafenib 60 Solazed ™ 60 investigational humanized monoclonal antibody 60 EFAPROXYN 60 Genz # 60 Nexavar ® 60 anticancer compound 60 Phase IIb trial 60 RLY# 60 Tavocept 60 BiovaxID 60 JAK1 60 MAGE A3 ASCI 60 Ceplene 60 vidofludimus 60 Phase Ib study 60 eltrombopag 60 Phase Ib clinical 60 radiation sensitizer 60 CYT# potent vascular disrupting 60 tolerability profile 60 Evoltra ® 60 APOPTONE 60 entinostat 60 elacytarabine 60 Telatinib 59 Alpharadin 59 L BLP# 59 pivotal Phase III 59 CA4P 59 virus HCV protease inhibitor 59 metastatic renal cell carcinoma 59 Octreolin 59 PEG PAL 59 sunitinib 59 mipomersen 59 ADVEXIN 59 Symadex 59 candidate CRLX# 59 ThermoDox ® 59 ZYBRESTAT 59 neratinib 59 IDX# 59 custirsen 59 JAK inhibitors 59 ridaforolimus 59 NGX# 59 FOLOTYN ® 59 pafuramidine 59 oritavancin 59 Poly ICR 59 forodesine HCl 59 Entereg R 59 Leukine 59 dirucotide MBP# 59 Torisel 59 oncology indications 59 Civacir 59 Folotyn 59 HCV protease inhibitor 59 refractory PTCL 59 Targretin 59 Zemiva TM 59 reslizumab 59 phase IIb trial 59 Lixivaptan 59 DR Cysteamine 59 HCD# [002] 59 Serdaxin 59 cancer immunotherapies 59 AzaSite Plus 59 albinterferon alfa 2b 59 CBLC# 59 OHR/AVR# 59 Amplimexon 59 SARMs 59 Phase #b/#a 59 SUTENT ® 59 lumiliximab 59 favorable pharmacokinetic profile 59 PLK1 SNALP 59 IMGN# 59 Urocidin 59 ocular formulation 59 ARIKACE ™ 59 lymphoma CTCL 59 alvimopan 59 Phase 2b 59 R#/MEM # 59 UPLYSO 59 HCV protease inhibitors 59 tezampanel 59 Dacogen injection 59 ELACYT 59 Atiprimod 59 nonclinical studies 59 Onalta ™ 59 BAY #-# 59 TYZEKA 59 ambrisentan 59 ozarelix 59 pharmacodynamic properties 59 ixabepilone 59 Clavis Pharma 59 deforolimus 59 Fibrillex TM 59 mertansine 59 subcutaneous formulation 59 refractory gout 59 TBC# 59 Bicifadine 59 AMR# 59 vemurafenib 59 Viramidine 59 bafetinib 59 receptor tyrosine kinase inhibitor 59 Azixa 59 BLA filing 59 rhThrombin 59 Panzem R 59 PSN# [002] 59 rNAPc2 59 EGFR inhibitors 59 Shigamabs ® 59 dasatinib Sprycel ® 59 oral taxane 59 huC# DM4 59 Personalized Immunotherapy 59 pegylated interferons 59 Fludara 58 cancer immunotherapy 58 pexiganan 58 L MTP PE 58 RGB # 58 neuroendocrine tumors 58 elvucitabine 58 StaphVAX 58 MAA submission 58 forodesine hydrochloride 58 MYDICAR ® 58 KNS # 58 oral Azacitidine 58 OXi# 58 Anticalin R 58 Restanza 58 PEGylated interferon beta 1a 58 enzastaurin 58 ALN RSV# 58 Chemophase 58 vismodegib 58 PNP inhibitor 58 recurrent glioblastoma 58 dexpramipexole 58 Fodosine 58 investigational pan BCR 58 preclinical studies 58 SEBIVO 58 temsirolimus 58 olaparib 58 GRN#L 58 clinical trials 58 R sorafenib tablets 58 BRAF inhibitor 58 Panzem 58 YONDELIS 58 preclinically 58 Phase 2b clinical trials 58 OPAXIO 58 Ophena TM 58 PROMACTA 58 zalutumumab 58 Quinamed 58 hypoxia activated prodrug 58 Onconase 58 dalbavancin 58 Reolysin 58 volociximab 58 ALN PCS 58 selective androgen receptor modulator 58 DAVANAT R 58 CCR5 antagonist 58 Troxatyl 58 Sebivo 58 maribavir 58 Zybrestat 58 Omigard 58 Perifosine 58 relapsed SCLC 58 MAXY G# 58 denufosol 58 Phase Ib clinical trials 58 talabostat 58 OncoVEX 58 IMC #B 58 belinostat 58 glufosfamide 58 Exelixis compounds 58 atrasentan 58 Evoltra 58 Tyrima 58 INTERCEPT platelets 58 relapsed refractory multiple myeloma 58 Vandetanib 58 Marqibo 58 PDE4 inhibitor 58 Telintra 58 BENLYSTA ® 58 IMC A# 58 BrachySil 58 PRTX 58 tremelimumab 58 bevacizumab Avastin ® 58 Nexavar sorafenib 58 NEUMUNE 58 proteasome inhibitor 58 cutaneous T cell 58 omacetaxine 58 ASA# 58 RDEA# 58 Phase 2b clinical 58 Phase 1b clinical 58 Phase IIb 58 COMFORT II 58 TRIOLEX 58 metastatic sarcomas 58 HCV infection 58 Trofex 58 Neuradiab 58 randomized Phase 58 Locteron 58 GV# [001] 58 therapeutic monoclonal antibody 58 VEGF receptor inhibitor 58 bendamustine 58 Virulizin ® 58 TPI ASM8 58 bavituximab 58 myeloproliferative disorders 58 targeted radiotherapeutic 58 sunitinib malate 58 dose cohort 58 DPP4 inhibitor 58 multi kinase inhibitor 58 Vicinium TM 58 XL# XL# 58 velafermin 58 carboplatin paclitaxel 58 VELCADE 58 MDV# 58 mitogen activated ERK kinase 58 rFIXFc 58 tolerability 58 antibody MAb 58 ProLindac 57 delafloxacin 57 Tarceva erlotinib 57 Hematide 57 depsipeptide 57 vascular disrupting agent 57 darapladib 57 Firazyr 57 rindopepimut 57 APF# 57 Azilect ® 57 metastatic melanoma 57 MGd 57 Phase IIa trial 57 ISIS # 57 LCP Tacro 57 novel VDA molecule 57 GLP toxicology studies 57 ceftaroline 57 MyVax ® 57 cannabinor 57 bardoxolone methyl 57 torezolid phosphate 57 Trizytek 57 eculizumab 57 visilizumab 57 dasatinib Sprycel 57 panitumumab 57 Aflibercept 57 castration resistant prostate cancer 57 celgosivir 57 mRCC 57 TEMODAL 57 non nucleoside HCV 57 metastatic RCC 57 DCVax R 57 Mepact 57 CytoFab 57 cell lymphoma CTCL 57 relapsed ovarian cancer 57 BENLYSTA 57 lubiprostone 57 HSP# inhibitor 57 biologic therapies 57 Hsp# inhibitor 57 Cimzia TM 57 PREOS R 57 AZILECT R 57 Hepatocellular Carcinoma HCC 57 Myocet 57 PDX pralatrexate 57 NP2 Enkephalin 57 Intravenous CP 57 riociguat 57 lintuzumab SGN 57 sorafenib tablets 57 MT# MEDI 57 MabCampath 57 lintuzumab 57 anti EGFR antibody 57 CYCLOSET 57 midstage trials 57 indolent NHL 57 myelofibrosis 57 Shigamabs R 57 Ceplene TM 57 eprotirome 57 MAXY alpha 57 Allovectin 7 r 57 histone deacetylase HDAC inhibitor 57 CB2 selective receptor agonist 57 Lymphoseek ® 57 SERMs 57 Phase #/#a trial 57 HER2 positive metastatic breast 57 generation purine nucleoside 57 Phase IIb clinical trials 57 Taxotere ® 57 drug conjugate 57 angiogenesis inhibitor 57 EndoTAG TM -1 57 Ceflatonin 57 CDP# 57 MEPACT 57 investigational monoclonal antibody 57 Fodosine TM 57 cilengitide 57 EOquin TM 57 ofatumumab 57 Cleviprex TM clevidipine 57 Phase #b/#a clinical 57 PHX# 57 Zemiva ™ 57 AZILECT ® 57 motesanib 57 Phase IIIb clinical 57 ataluren 57 B CLL 57 BCX# 57 Solazed 57 Cannabinor 57 preclinical 57 tesmilifene 57 isoform selective 57 ATryn R 57 Ziopharm 57 Pradefovir 57 AEGR 57 adecatumumab 57 romidepsin 57 aleglitazar 57 PRX# 57 faropenem medoxomil 57 JAK2 inhibitor 57 chronic HCV infection 57 compound INCB# 57 REMICADE ® 57 hematological malignancies 57 SPRYCEL ® 57 elagolix 57 Acapodene 57 anti angiogenic therapy 57 ATryn ® 57 Carfilzomib 57 vascular disrupting agents 57 thymalfasin 57 lupus nephritis 57 liprotamase 57 ospemifene 57 Imprime PGG 57 thalidomide Thalomid 57 ApoB SNALP 57 OMP #M# 57 refractory CLL 57 mTOR inhibitors 57 ostarine 57 liposomal doxorubicin 57 LymphoStat B 57 Plenaxis TM 57 hematologic malignancies 57 voclosporin 57 phase IIa 57 CINTREDEKIN BESUDOTOX 57 Oncophage 57 Raptiva ® 57 ONCONASE 57 XL# XL# XL# 57 SAR# [004] 57 regadenoson 57 RH1 57 Relivar 57 Nexavar 57 Increlex ® 57 NSCLC 57 Iluvien ® 57 Genentech Roche 57 Hsp# inhibition 57 Apaziquone 57 Phase 2a clinical 57 cetuximab Erbitux R 57 IMiDs 57 hematological cancers 57 Anturol 57 docetaxel chemotherapy 57 imetelstat 57 PEP# [003] 57 Cimzia 57 Aplidin 57 Tivozanib 57 velafermin belinostat 57 Bronchitol 57 brentuximab vedotin 57 IAP inhibitors 57 TACI Ig 57 Exherin 57 palifermin 57 chemotherapy induced neutropenia 57 Votrient 57 DOS# 57 CRLX# 57 linaclotide 57 TroVax 57 Technosphere Insulin 57 Phase Ib II 57 Excellarate 56 Cinryze ™ 56 Behcet uveitis 56 tosedostat 56 Ostarine 56 sorafenib Nexavar 56 tezampanel NGX# 56 TKM ApoB 56 ALN TTR# 56 refractory APL 56 ALD# 56 Celator 56 Neulasta ® 56 EndoTAG 56 PrevOnco 56 Stimuvax R 56 ibudilast 56 Oral NKTR 56 anidulafungin 56 SILENOR TM 56 lesinurad 56 Mozobil 56 ongoing Phase 1b 56 posaconazole 56 CCR9 antagonist 56 Gemzar ® 56 epothilone 56 GnRH antagonist 56 Nanobody 56 metastatic hormone refractory 56 Laquinimod 56 LEUKINE 56 LibiGel ® 56 PSMA ADC 56 faropenem 56 Daclizumab 56 IIa trial 56 Soliris TM eculizumab 56 DAVANAT ® 56 ATIR TM 56 TREANDA 56 Plenaxis R 56 rALLy trial 56 Herceptin trastuzumab 56 hepatocellular cancer 56 relapsing remitting multiple sclerosis 56 cetuximab Erbitux 56 NVA# 56 trastuzumab Herceptin R 56 cysteamine 56 REOLYSIN ® 56 Zolinza 56 PCA3 test 56 telaprevir 56 ATL/TV# 56 tranilast 56 farletuzumab 56 refractory metastatic colorectal cancer 56 RhuDex ® 56 trastuzumab DM1 T DM1 56 SinuNase 56 ENMD 56 dose escalation trial 56 Satraplatin 56 Tarceva TM 56 ELND# 56 molecular imaging radiopharmaceutical 56 Defibrotide 56 imatinib Gleevec ® 56 Puricase 56 Revlimid lenalidomide 56 EDEMA3 56 oral Xeloda 56 Clolar ® 56 phase IIb study 56 Gemin X 56 Vascular Wrap TM 56 dacarbazine 56 humanized monoclonal antibody 56 G#DT 56 nitazoxanide 56 pegfilgrastim 56 cariprazine 56 opioid induced bowel dysfunction 56 ACAPODENE TM 56 recurrent NSCLC 56 LB# [003] 56 predictive biomarkers 56 Taxotere R 56 sumatriptan DosePro 56 hypercalcemia 56 LY# [003] 56 ZADAXIN ® 56 Dapagliflozin 56 Indaflex TM 56 abiraterone acetate 56 orBec ® 56 metastatic castration resistant 56 Alocrest 56 Zelrix 56 Phase 2a 56 TRISENOX 56 alpha interferons 56 refractory chronic lymphocytic 56 Synavive 56 telbivudine 56 QuatRx 56 liposomal formulation 56 CIMZIA ™ 56 Combo Stent 56 lapatinib Tykerb 56 T DM1 56 ONTAK 56 panitumumab Vectibix 56 Navelbine ® 56 MEK inhibitor 56 leukemia AML 56 Cetrorelix 56 hereditary deficiency 56 ALN TTR 56 gefitinib Iressa 56 aflibercept 56 pitavastatin 56 LE DT 56 superficial bladder cancer 56 Opexa 56 incyclinide 56 Evoltra TM 56 Canvaxin 56 BrachySil TM 56 bosutinib 56 non squamous NSCLC 56 Rebif ® 56 Fx #A 56 CD# antibody [001] 56 Triolex 56 vorinostat 56 ZACTIMA 56 Veronate 56 Helsinn Healthcare 56 BCR ABL inhibitors 56 SEPET TM 56 LymphoStat B TM 56 INC# 56 Simulect 56 OMNARIS HFA 56 CIMZIA TM 56 Tarvacin 56 dose escalation 56 fipamezole 56 Voraxaze ™ 56 apaziquone 56 ISTODAX 56 oral methylnaltrexone 56 Irinotecan 56 BYDUREON 56 ThermoDox R 56 multicenter Phase III 56 dose cohorts 56 APTIVUS 56 INTEGRILIN ® 56 vinorelbine 56 HepeX B 56 Copegus ribavirin 56 Virulizin R 56 TriRima 56 Aurexis 56 bicifadine 56 gemcitabine Gemzar ® 56 epigenetic therapies 56 hepatocellular carcinoma 56 systemic immunosuppressive drugs 56 tafamidis 56 Trofex TM 56 BRIM2 56 iclaprim 56 cSSSI 56 cardiac toxicity 56 FRDA 56 glucokinase activator 56 isavuconazole 56 leading oral taxane 56 Altastaph 56 Ceplene R 56 ThermoDox 56 mifamurtide 56 CUDC 56 Syncria 56 VitiGam 56 Tocosol Paclitaxel 56 Aviptadil 56 iSONEP 56 micafungin 56 cethromycin 56 investigational therapies 56 confirmatory Phase 3 56 Onalta 56 sorafenib Nexavar ® 56 pan HDAC inhibitor 56 miconazole Lauriad 56 Fludara ® 56 Linjeta TM 56 S/GSK# 56 Mpex 56 delta isoform 56 PrevOnco ™ 56 successfully commercialize Iluvien 56 IL# PE#QQR 56 Vaccinex 56 S1P antibody 56 lenalidomide Revlimid R 56 galiximab 56 Velcade bortezomib 56 hepatitis C HCV 56 temozolomide 56 CG# [003] 56 ketolide antibiotic 56 DU #b 56 CONBRIZA 56 seliciclib CYC# 56 TMC# [002] 56 OMNARIS Nasal Spray 56 VivaGel TM 56 AzaSite Xtra 56 Arcalyst 56 DermaVir Patch 56 Sorafenib 56 PROVENGE 56 Kamada AAT 56 Aptivus 56 pazopanib 56 DCVax ® 56 Ventavis 56 NPSP# 56 Campath ® 56 alemtuzumab Campath 56 MAbs 56 Erbitux cetuximab 55 bendamustine HCl 55 Cellegesic 55 octreotide implant 55 mycophenolate mofetil 55 palifosfamide 55 MBP# dirucotide 55 HERmark 55 Cloretazine 55 Onco TCS 55 ACTEMRA TM 55 Tarmogen 55 oncolytic virus 55 Gefitinib 55 RAPAFLO 55 TYKERB 55 MAb 55 histone deacetylase inhibitor 55 zanolimumab 55 SRT# [003] 55 kinase inhibitor 55 demonstrated antitumor activity 55 dimebon 55 Exherin TM 55 tecarfarin 55 Increlex 55 cediranib 55 oxymorphone ER 55 Octreotide 55 CTA# Injection 55 tramiprosate Alzhemed TM 55 Pazopanib 55 CYC# 55 Adlea 55 EndoTAG TM 55 Cloretazine ® 55 hematologic disorders 55 ELIQUIS 55 CD# CEA 55 orally bioavailable 55 Avicena 55 synthetic retinoid 55 pharmacological chaperone 55 gemifloxacin 55 ARIKACE 55 SUTENT 55 bazedoxifene 55 Taxotere chemotherapy 55 chlorambucil 55 Locteron ® 55 BEMA TM Fentanyl 55 SCCHN 55 Doxil ® 55 IAP inhibitor 55 BiovaxID TM 55 EGEN 55 refractory Hodgkin lymphoma 55 Telcyta 55 efficacy tolerability 55 PROVENGE sipuleucel T 55 Tarvacin TM 55 anti leukemic 55 Tolerx 55 Phase III 55 BZL# 55 methylnaltrexone 55 MyVax personalized immunotherapy 55 drug GAP #B# 55 triphendiol 55 veltuzumab 55 VQD 55 TRANSDUR Sufentanil 55 budesonide foam 55 TroVax ® 55 PD LID 55 midstage studies 55 NEBIDO 55 Neuvenge 55 TLR8 agonist 55 brivaracetam 55 RSR# 55 corticosteroid dexamethasone 55 MGCD# [002] 55 oral Factor Xa 55 Santhera 55 Factor Xa inhibitor 55 MoxDuo IR 55 Glufosfamide 55 prostate cancer CRPC 55 TKI therapy 55 Telavancin 55 alemtuzumab 55 Genasense ® 55 Seliciclib 55 Phase IIa clinical trials 55 Vilazodone 55 immunomodulatory therapy 55 GRN# 55 non metastatic osteosarcoma 55 Cethrin 55 Vectibix panitumumab 55 dasatinib 55 Diamyd ® 55 amifampridine phosphate 55 TNFerade 55 Azedra TM Onalta TM 55 teplizumab 55 bifeprunox 55 tolerability profiles 55 HCV polymerase inhibitor 55 DPX Survivac 55 Phase III HEAT 55 NXL# 55 Interferon alpha 55 TYSABRI 55 EpiCept NP 1 55 CORT # 55 pegylated interferon alpha 55 APPRAISE 55 Treanda 55 XYOTAX TM 55 antibody MT# 55 danoprevir 55 Xcytrin R 55 cangrelor 55 candidate TNFerade biologic 55 Aryplase 55 EGFR targeting 55 pharmacokinetic PK study 55 Hsp# inhibitors 55 melphalan prednisone 55 edoxaban 55 initiate Phase 1b 55 PARP inhibitor 55 AeroLEF TM 55 DDP# 55 HEPLISAV 55 Reverset 55 Guanilib